Rubius Therapeutics

$10.31
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.36 (+29.43%) Today
-$0.07 (-0.67%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell RUBY and other stocks, options, and ETFs commission-free!

About RUBY

Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan on April 26, 2013 and is headquartered in Cambridge, MA. The listed name for RUBY is Rubius Therapeutics, Inc. Common Stock.

CEO
Pablo J. Cagnoni
Employees
204
Headquarters
Cambridge, Massachusetts
Founded
2013
Market Cap
1.19B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.21M
High Today
$10.86
Low Today
$8.25
Open Price
$8.35
Volume
5.11M
52 Week High
$15.99
52 Week Low
$3.35

RUBY Earnings

-$0.60
-$0.55
-$0.50
-$0.45
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.49 per share
Actual
-$0.50 per share

You May Also Like

CPRI
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure